Sofosbuvir/Ledipasvir

索磷布韦/雷迪帕韦

Report date: 2026/03/13 20:02:36
First In Class

Base Information

Drug NameSofosbuvir/Ledipasvir
Drug Alias Name来迪派韦索磷布韦夏帆宁Harvoni
ClassificationSmall molecules
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsNonstructural protein 5A inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseNonstructural protein 5A
Therapy Area/IndicationsSubstance Abuse, IntravenousFibrosisbeta-Thalassemia +[10] 
Global Approved IndicationsHepatitis C, ChronicHepatitis C
Approved Indications in ChinaHepatitis C, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date2014/10/10
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsYes LedipasvirSofosbuvir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesWake Forest University Health SciencesGilead Sciences International LtdGilead Sciences Inc +[6] 
Inactive CompaniesGenuine Research Center, EgyptThe Macfarlane Burnet Institute For Medical Research And Public Health LtdGilead Sciences Ltd +[7] 
Active Indicationsbeta-ThalassemiaPorphyria Cutanea TardaHematologic Neoplasms +[6] 
Inactive IndicationsSubstance Abuse, IntravenousFibrosisCryoglobulinemia +[4] 

Other Information

ATC CodeJ05AP51
Related LinksWikipediaKEGG